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Chlordane is a polychlorinated hydrocarbon that causes liver enlargement and induces
mixed-function oxidases similar to those induced by phenobarbitone in the mouse. We have
assessed the hepatocarcinogenicity (after 2 years) and the time course (over 6 months) of liver
and thyroid cell proliferation in C57B1/1OJ mice exposed to chlordane at 50 ppm in the diet,
using the same batch of food for both carcinogenicity and cell proliferation studies. In the
bioassay, 15/39 survivors had hepatocellular adenomas and a further 5/59 had carcinomas, com-
pared with less than 5% incidence of primary hepatic tumors in concurrent controls. Among
unscheduled deaths, 1/40 adenomas and 2/40 carcinomas were recorded. There were no macro-
scopically observed thyroid lesions. In the proliferation study, mice were killed on days 4, 5, 8,
15, 29, 99, and 190 after the start ofdosing. Withdrawal groups were included from days 29 to 99
and from days 190 to 247. Replicating cells were labeled via bromodeoxyuridine delivered by
osmotic minipump for 3 days before necropsy. In the thyroid, the peak labeling index (LI) was
seen on day 5 (LI = 5.99 t 2.90%k versus 1.00 ± 20%o in controls), while in the liver the peak was on
day 8 (9.0 ± 1.6% versus 0.5 ± 0.4% in controls). Both organs had an elevated LI for the first
month of dosing, but while the thyroid follicular LI was similar to control at 99 and 190 days,
the liver LI was significantly elevated at all time points except in the withdrawal groups.
However, there appeared to be a trend toward the control LI at longer time points, suggesting
that elevated hepatocyte replication may not have occurred throughout the duration of the
oncogenicity study.
Introduction
The kinetic response of hepatocytes to chronic insult
by nongenotoxic hepatocarcinogens has been the subject
ofconsiderable recent interest. In several studies on the
rodent liver, attention has been focused on the signifi-
cance ofobservations ofprotracted proliferative activity
in hepatocytes ofrats exposed to inducers ofcytochrome
P450 type IVAl ofdifferent carcinogenic potencies (1-3).
Little information is currently available on the existence
of such prolonged proliferative activity in the livers of
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mice of the C57B1 strain, which has a low background
incidence ofspontaneous livertumors.
In the present study, the proliferative response of
hepatocytes and thyroid follicular cells of the C57B1/
1OJ mouse to chlordane was analyzed. The C57B1/1J
mouse has a low incidence of hepatocellular and thy-
roid tumors and is used routinely for cancer bioassays
within ICI. Chlordane was chosen as the test article
for the studies reported here because of its known
oncogenicity to the liver of both B6C3F1 and C57B1/6
mice (4-6) and because it is known to induce mixed-
function oxidase enzymes similar to those induced by
phenobarbitone (isozyme form II) (7,8). Thyroid follicu-
lar cells were analyzed for proliferative activity (as
well as hepatocytes) to monitor any long-term
response of the thyroid to the increased thyroid hor-
mone metabolism, which would be expected to result
from increased cytochrome P450 activity in the liver
and increased liver size (9).
Two animal studies are reported in this paper. ABARRASSETAL.
chronic hepatocarcinogenicity assay was conducted
with chlordane at 50 ppm in the diet ofC57B1/10J mice
for 2 years, and a parallel study of 6 months' duration
with interim kills was conducted for analyzing liver
histopathology and hepatocyte and thyroid follicular
cell proliferation during preneoplastic stages. The
same batch offood was used for both studies.
Materials and Methods
Hepatocarcinogenicity Assay
One hundred male C57B1/10J mice were given chlor-
dane at 50ppminthedietforupto24months. Atnecrop-
sy, a thorough macroscopic examination was conducted,
and liver samples were placed in neutral-buffered forma-
lin for subsequent sectioning and histopathological analy-
sis. The control incidence of hepatocellular tumors was
derived from aconcurrentbioassaywithin ICI.
Cell Proliferation Study
Groups offive male mice were killed on days 2, 3, 4, 5,
8, 15,29, 99, and 190afterthe start ofdosing. Withdrawal
groups were included from days 29 to 99 and 190 to 247
and control groups on days 4, 29, 99, and 190. Replicating
cells were labeled by infusing 5-bromo-2'-deoxyuridine
(BrdU; 15 mg/mL at 1 gL/hr via mini-osmotic pumps
(model 1003D) implanted subcutaneously 3 days before
necropsyondays4, 5,8, 15,29, 190, and247.
Samples were put in formalin from liver (left and
right lateral and median lobes), thyroid, and duodenum
(the latter as a control for BrdU immunostaining).
Serial sections were cut from each block to permit
hematoxylin and eosin (H&E) and anti-BrdU immuno-
staining. At least 1000 cells from each liver lobe and
the thyroid were scored for labeled nuclei.
Results
Histopathology
HepatocarcinogenicityAssay. The body weight data
from the cell proliferation study show a reduction of
12% in chlordane-treated mice after 190 days. This
indicates that the dose of 50 ppm represents an
approximate maximum tolerated dose. No macroscopic
abnormalities were noted in the thyroids at necropsy
(these tissues were not examined histopathologically).
The liver histopathology findings are summarized in
Table 1. At 2 years, the overall incidence ofhepatocellu-
lar tumors was about 50%, with a higher incidence of
adenomas than carcinomas. Among the unscheduled
deaths, the first tumor was not observed until 21 months
ofdosing. The incidence of all types ofhepatic tumor in
400 untreated male C57B1/1OJ mice was 2.0% after 2
years in arecent colony control study(data not shown).
Cell Proliferation Study. THYROID. No histopatho-
logical abnormalities were noted in the thyroid at any
Table 1. Incidence oftumors in livers ofC57B1/1OJ mice
after 22-24 months of50 ppm chlordane in the diet.
Tumor type Terminal kills Incidental kills Totals
Hepatocellular adenoma 15/39 1/40 16/79
Hepatocellular carcinoma 5/39 2/40 7/79
All tumors 20/39 3/40 23/79
The incidence ofall types ofhepatic tumors in 400 untreated male
C57B1/1OJ mice was 2.5% after2 years in a recent colony study
(unpublished data).
time point on this study.
LIVER. Body weights in the treated animals were
reduced by 12% relative to controls after 190 days of
dosing. The time course of the change in liver: body
weight ratio as a percentage of control is shown in
Figure 1. Liver weights increased in a linear fashion to
150% of control values after 32 months of dosing and
remained at this level at the 6-month time point.
Table 2 contains a summary of the salient histo-
pathological findings. There was a minimal increase in
the number of hepatocyte mitoses on day 2, and this
persisted through all time points until day 99. This
increase was characterized by the presence of approx-
imately three to six mitotic figures in one or more liver
lobe sections. There was no difference between the
groups on day 190. Centrilobular hepatocyte hypertro-
phy was seen from day 4 onward, and this increased in
severity with the duration oftreatment. All chlordane-
treated mice showed severe centrilobular hepatocyte
hypertrophy on days 99 and 190, and hypertrophy was
still present afterup to 2 months withdrawal.
Cell Proliferation
Thyroid. The data for thyroid follicular cell prolifer-
ation was summarized in Figure 2. The peak labeling
index (LI) ofthyroid cells was observed after 5 days of
chlordane treatment (6.0 ± 2.9% in treated versus 1.0 ±
0.2% in controls). The LI was significantly greater in
chlordane-treated mice than in control at all time
points up to and including day 99 (p < 0.01), but there
was no significant difference after 190 days. There was
no observed elevation ofLI among withdrawal animals.
The distribution of replicating cells among individual
follicles was also recorded during the study, but there
was no evidence that any individual follicles contained
an excessive numberofstained nuclei (data not shown).
Liver. Qualitative examination of the slides revealed
no clear zonal distribution of labeled hepatocytes in
control or treated groups. The time course of hepato-
cyte proliferation is shown in Figure 3.
The peak hepatocyte LI was observed after 8 days of
chlordane treatment (9.0 ± 1.6% in treated versus 0.5 ±
0.4% in controls). This decreased relatively quickly to 5.3
± 1.1% byday29, but thereafterthe rate ofdecrease was
slower. By day 190 (the end ofdosing), the LI in treated
animals was still2-fold higherthan in controls (1.7 ± 0.5%
versus 0.8 ± 0.2%). The LI among withdrawal animals
was compatiblewith concurrent controlsin each case.
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FIGURE 1. Time course ofchange ofliver/body weight ratios ofchlordane-treated mice, expressed as percentage ofcontrol.
Discussion
These data show that chlordane is hepatocarcinogenic
to male C57B1/1OJ mice at 50 ppm in the diet, but it
does not obviously induce thyroid tumors. Chlordane
induced extensive liver enlargement, which was due to
both sustained hepatocyte hypertrophy as shown by
histopathology, and to hyperplasia, as shown by immuno-
cytochemical detection of S-phase hepatocyte nuclei. In
the thyroid, follicular cell turnover was stimulated up to
the 3-month time point, but this was not accompanied by
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any change in thyroid pathology. Among control mice,
the rate of hepatocyte turnover ranged from 0.5% at 6
weeks of age to a maximum of 1.9% at 10 weeks.
Subsequent observations were 1.0% at 19 weeks and
0.76% at 32 weeks. These results are comparable with
data reported for the B6C3Fj mouse (10,11), suggesting
that there is little difference in the rate of hepatocyte
replication in B6C3Fj and C57B1/ 10J mice. A similar
comparison is not available for the thyroid, where the
LI in control C57B1/1OJ mice was 1.0% at 6 weeks of
age and reduced to 0.2% by the 6-month time point.
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FIGURE 2. Time course ofthyroid follicular cell S-phase labeling. A minimum of 1000 thyroid follicular cells were scored per section.
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Table 2. Summary ofhistopathological findings in H&E sections ofliver from C57B1/1OJ mice fed chlordane at 50 ppm in
the diet for up to 6 months.
Days after start ofdosing
Treatment 2 3 4 5 8 15 29 29+WD 99 190 190+WD
Control (5) (5) (5) (5)
Mitoses
Hypertrophy
50 ppm Chlordane (5) (5) (10) (10) (10) (5) (5) (5) (4) (5) (4)
Mitoses 2 4 1 6 6 1 1 1
Hypertrophy
Minimal 1
Mild 2 10
Moderate 5 5 5 2
Severe 4 5 2
WD, withdrawal; see text for details.
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FIGURE 3. (A) Time course ofhepatocyte S-phase labeling. The results from the individual liver lobes have been amalgamated, so at least 4000
hepatocytes were scored from each animal. (B) Time course ofhepatocyte labeling, shown as a line graph with a linear time scale.
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It has been proposed that hepatocyte proliferation
plays a pivotal role in the tumorigenicity of various
nongenotoxins that cause liver enlargement in rodents
(1,3,12). Two phases of the proliferative response
("acute" and "sustained") have been identified, and we
discuss these in relation to our data with chlordane.
Acute Proliferative Response
With chlordane, the peak of hepatocyte LI was
observed after 8 days of dosing and the initial wave of
hepatocyte proliferation after the start of dosing lasted
for 4 weeks. This is later than that reported in some
other studies in mice with different compounds. Thus,
Styles et al. (13) noted a maximum duration ofthe prolif-
erative wave aftermethylclofenapate treatment ofabout
7 days, and Ward et al. (14) reported no elevated hepato-
cyte proliferation in mice given [3H] thymidine after 14
days of phenobarbitone treatment. It is, however, com-
patible with the results of Klaunig et al. (10) and Seglin
et al. (15), who report elevated hepatocyte proliferation
in B6C3F1 mice treated with phenobarbitone or hexa-
chlorocyclohexane (HCH; another polychlorinated
hydrocarbon used as a pesticide) for 3, 7, and 14 days.
Additionally, Lindroos et al. (16) have recently demon-
strated elevated hepatocyte LI in rats treated with phe-
nobarbitone or HCH for up to 10 days. The comparison
with other reported data is difficult because factors such
as different labeling procedures, age ofthe animals used,
and different mouse strains need tobetaken into account.
The time course of mouse hepatocyte proliferation
with methyl clofenapate (which also has a long half-
life) is inversely proportional to the dose (13), with a
shorter response at higher doses. Although the dose of
chlordane given in the present study is the effective
maximum tolerated dose for an oncogenicity study, it
would be ofinterest to determine the shape ofthe pro-
liferative response at higher subacute doses.
Sustained Proliferative Response
Hepatocyte proliferation was elevated between days
29 and 190 with chlordane, although, in contrast to
findings with the potent nongenotoxic hepatocarcino-
gens, methyl clofenapate and Wy 14,643 in the rat
(1,2,17), the degree of elevation constantly decayed
duringthis period. Chlordane also induced tumors with
a much longer latency period than these other com-
pounds, a finding that may relate to the (predicted)
continued decay in cell turnover after 6 months.
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